BioWorld

Oct. 31, 2007

Amgen Spinout Relypsa Starts Business With $33M Series A

If the story of newly established Relypsa Inc., a company created to develop nonabsorbed polymeric drugs for renal and cardiovascular diseases, sounds more than a little familiar, that's probably because it is. (BioWorld Today) Read More

India's Glenmark in $350M Deal With Lilly For Pain Compound

Acceleron Series C Gets $31M For Bone, Muscle Growth Bids

Genoptix IPO Soars 56 percent; RXi Files For Independence

Neurobiological Offering Nets $56 Million For Viprinex Trials

Other News To Note

U.S. Patent Disclosures

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 9, 2025.

Red blood cells in an artery with cholesterol

In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

BioWorld

In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...

Corestemchemon preps US BLA filing for stem cell ALS therapy

BioWorld

Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...

The Nasdaq Stock Exchange headquarters in New York

Omada, Caris arrivals continue med-tech IPO hot streak

BioWorld MedTech

Omada Health Inc. rang the opening bell on the New York Stock Exchange on June 6, marking its first day as a public company, but it won’t be the most recent IPO...